being substituted by either a leucine (R271L) or a glutgated ion channel receptors, culminating in opening amine (R271Q) (Shiang et al., 1993) . R271 lies at the of the integral ion channel pore. Human hereditary external vestibule of the ion channel pore and forms part hyperekplexia, or startle disease, is caused by mutations of the extracellular loop linking the second and third in both the intracellular or extracellular loops flanking membrane-spanning domains (the M2-M3 loop). The the pore-lining M2 domain of the glycine receptor α1 physiological effect of these mutations is to reduce the subunit. These flanking domains are designated the glycine efficacy and single channel conductance of recom-M1-M2 loop and the M2-M3 loop respectively. We binant homomeric and heteromeric GlyRs (Langosch et al., show that four startle disease mutations and six addi-1994; Rajendra et al., 1994 Rajendra et al., , 1995a . In addition, both tional alanine substitution mutations distributed mutations converted β-alanine and taurine from full agonthroughout both loops result in uncoupling of the ists into competitive antagonists without dramatically ligand binding sites from the channel activation gate.
(GlyR) chloride channel. Two separate point mutations at the same base pair in the gene encoding the human GlyR Fast synaptic neurotransmission is mediated by trans-α1 subunit resulted in the arginine at position 271 (R271) mitter-activated conformational changes in ligandbeing substituted by either a leucine (R271L) or a glutgated ion channel receptors, culminating in opening amine (R271Q) (Shiang et al., 1993) . R271 lies at the of the integral ion channel pore. Human hereditary external vestibule of the ion channel pore and forms part hyperekplexia, or startle disease, is caused by mutations of the extracellular loop linking the second and third in both the intracellular or extracellular loops flanking membrane-spanning domains (the M2-M3 loop). The the pore-lining M2 domain of the glycine receptor α1 physiological effect of these mutations is to reduce the subunit. These flanking domains are designated the glycine efficacy and single channel conductance of recom-M1-M2 loop and the M2-M3 loop respectively. We binant homomeric and heteromeric GlyRs (Langosch et al., show that four startle disease mutations and six addi-1994; Rajendra et al., 1994 Rajendra et al., , 1995a . In addition, both tional alanine substitution mutations distributed mutations converted β-alanine and taurine from full agonthroughout both loops result in uncoupling of the ists into competitive antagonists without dramatically ligand binding sites from the channel activation gate.
affecting their binding affinities (Laube et al., 1995 ; We therefore conclude that the M1-M2 and M2-M3 Rajendra et al., 1995a) . As these results are consistent loops act in parallel to activate the channel. Their with an uncoupling of the agonist binding process from locations strongly suggest that they act as hinges the channel activation gate, it was concluded that R271 governing allosteric control of the M2 domain. As the formed a crucial component of the allosteric signal transmembers of the ligand-gated ion channel superfamily duction pathway (Langosch et al., 1994; , share a common structure, this signal transductionIntroduction and R271Q mutations, convert taurine and β-alanine into competitive antagonists with little disruption to their Fast synaptic neurotransmission in the mammalian central binding affinities. The I244N mutation also results in nervous system is mediated by members of the liganda dramatic reduction in taurine efficacy. These results gated ion channel (LGIC) superfamily, which includes demonstrate that the startle disease mutations may act by receptors for acetylcholine, GABA A , serotonin and glycine disrupting the allosteric transduction (or gating) process (Grenningloh et al., 1987; Schofield et al., 1987; Maricq between ligand binding and channel activation and raise et al., 1991) . These channels, which are located in the the possibility that the M1-M2 loop and the M2-M3 loop post-synaptic membrane, are opened by pre-synaptically act as the structural components mediating this process. released neurotransmitter and permit an ionic flux which
To investigate this possibility, we constructed sequential changes the membrane potential. Receptors of this family alanine substitution mutants of all residues in the M1-M2 consist of five similar membrane-spanning subunits intracellular loop and the M2-M3 extracellular loop and arranged in a ring to form a central ion-conducting pore.
for each mutant GlyR measured the binding affinities of The subunits of the different receptor types each comprise taurine and β-alanine and their agonist efficacies relative a large N-terminal extracellular domain, which contains to glycine. Since numerous mutations in both domains the ligand binding sites and four putative membrane did indeed reduce or eliminate the taurine and β-alanine spanning domains (M1-M4), the second of which forms efficacies with minimal change to their binding affinities, the channel-lining α-helix (reviewed in Devillers-Thiery we conclude that both domains act in parallel to activate et al., 1993; Karlin and Akabas, 1995) . Since the ligand the channel. The locations of these domains suggest they binding domain is distant from the M2 region (Valenzuela et al., 1994; Unwin, 1995) , channel activation requires act as hinges to allow the M2 domain to move with . In this and all subsequent figures, the glycine dose-response curves are normalized to 1 and the β-alanine and taurine dose-response curves are normalized to the maximal glycine-activated current for each mutant GlyR. The data for the R271L and R271Q mutant GlyRs in (E) and Figure 4 are reproduced from Rajendra et al. (1995a). respect to the rest of the protein. Additionally, we show disrupt the function of the human α1 GlyR homomer: I244N (Rees et al., 1994) , K276E (Elmslie et al., 1996) that two intracellular mutations (W243A and I244A) also dramatically increase the desensitization rate, suggesting and Y279C (Shiang et al., 1995) . For each mutant GlyR, we examined the agonist efficacies of taurine and β-alanine they form a link between the mechanisms mediating channel activation and desensitization.
relative to glycine, the concentration of each agonist required for half-maximal current activation (EC 50 ) and, in mutant GlyRs where β-alanine and taurine exhibited
Results
partial or no agonist efficacy, the concentration required for half-maximal inhibition of glycine-gated currents (IC 50 ).
Human startle disease mutations act by disrupting transduction
Sample electrophysiological responses from cells expressing these mutant GlyRs are shown in Figure 1A All experiments described in this report were performed on human α1 homomeric GlyRs recombinantly expressed D, averaged dose-response curves are shown in Figure  1E and the results of all electrophysiological measurements in mammalian HEK 293 cells. Taurine and β-alanine act as full agonists of human α1 GlyRs when expressed in are summarized in Table I . The binding properties of the competitive antagonist [ 3 H]strychnine were also examined this system (Pribilla et al., 1992; Rajendra et al., 1995a,b) , although they act as partial agonists of the same GlyRs with the dissociation constant (K d ), number of expressed receptors (B max ) and inhibition constants (K i ) for glycine, when expressed in Xenopus oocytes (Schmieden et al., 1992; Laube et al., 1995) .
β-alanine and taurine displacement of bound [ 3 H]strychnine being determined for wild-type and mutant GlyRs. We sought to investigate the mechanism by which the following recently identified startle disease mutations Averaged results from all binding experiments are summar- Values are given as mean Ϯ SE in cases where n ജ 3. In cases where n Ͻ 3, individual values are shown. Min I β-ala /I gly and Min I tau /I gly represent the mean proportional glycine-gated currents remaining in the presence of 100 mM β-alanine or taurine respectively. Hill coefficients are not displayed as there was no significant difference in Hill coefficient values between mutant and wild-type GlyRs. In both Tables I and II data for R271L and R271Q mutant GlyRs only are reproduced from Rajendra et al. (1995a) . a Parameters that could not be quantified as currents were either non-existent or too small to measure. b Not determined.
ized in Table II . Hill coefficients were determined for all The K276E and Y279C mutations also resulted in large (73-to 100-fold) increases in the glycine EC 50 with respect electrophysiological and binding experiments. However, since the Hill coefficients for all mutant GlyRs were not to the wild-type value ( Figure 1D and E and Table I ). However, for both mutant GlyRs, the strychnine K d and significantly different from wild-type GlyR values, they have been omitted from Tables I and II for reasons B max values were not significantly different to wild-type values (Table II) , suggesting that the mutations did not of brevity.
In the K276E and Y279C mutant GlyRs, concentrations induce non-specific alterations in the structure of the N-terminal domain or reduce the efficiency of GlyR of up to 100 mM of either taurine or β-alanine failed to activate detectable currents, although glycine-gated expression. The ability of bound glycine to displace [ 3 H]strychnine was, however, significantly diminished in currents were readily observed ( Figure 1A and Table I ). Indeed, both mutations converted taurine and β-alanine both K276E and Y279C mutant GlyRs, although the changes in taurine and β-alanine K i values were less into full antagonists of currents activated by half-saturating concentrations of glycine. An example of taurine inhibition dramatic (Table II) . All of these measured properties indicate that the K276E and Y279C mutant GlyRs exhibit of currents activated by 2 mM glycine in the K276E mutant GlyR is shown in Figure 1B . Averaged IC 50 a similar phenotype to that of the R271L and R271Q mutant GlyRs. It may therefore be concluded that each of values for taurine and β-alanine inhibition of glycinegated currents in the K276E mutant GlyR are shown in these startle disease mutations acts in a similar manner to disrupt the ability of the receptor to convert agonist Table I. We also confirmed that 100 mM taurine or β-alanine completely inhibited glycine-gated currents in binding into channel activation. For brevity, this set of properties is designated the 'complete' disruption phenothe Y279C mutant GlyR (n ϭ 3 for each), but as glycinegated currents were particularly small in this mutant GlyR type, as the transduction mechanism for taurine and β-alanine is completely disrupted. As each of the mutated (Table I) , the IC 50 values could not be measured precisely. residues (R271, K276 and Y279) are distributed throughout regained but B max was significantly reduced (42%) relative to the wild-type value (Table II) . the M2-M3 loop, they raise the possibility that this entire loop may form an important structural component of the Since the β-alanine and taurine efficacies and glycine EC 50 values of the I244N mutant GlyR lie between those allosteric signal transduction mechanism.
In the I244N mutant GlyR, taurine was converted into of the wild-type GlyR and the K276E and Y279C mutated GlyRs, the I244N mutation may be considered to partially a partial agonist, although β-alanine remained virtually a full agonist ( Figure 1A and E and Table I ). Taurine was disrupt the agonist transduction mechanism and is consequently designated as having a 'partial' disruption also converted into a partial antagonist of glycine-gated currents ( Figure 1C ) and, as expected, β-alanine did not phenotype. These properties imply that the M1-M2 loop, like the M2-M3 loop, is important for transducing agonist display detectable antagonism (n ϭ 3; data not shown). In the I244N mutant GlyR, the average EC 50 values of binding into channel activation. glycine, β-alanine and taurine were increased by a factor of 10-15 over their respective wild-type values ( Figure  Residues in the M1-M2 and M2-M3 loops control agonist efficacy 1E and Table I ). We were unable to detect significant [ 3 H]strychnine binding in this mutant GlyR, although in To investigate further the possibility that the M1-M2 and M2-M3 loops may act in parallel to mediate activation electrophysiological experiments we confirmed that 1 μM strychnine did completely inhibit currents activated by a of the channel, we sought to examine the contribution of all residues in both loops to this process. As the various half-saturating concentration (200 μM) of glycine (n ϭ 2: data not shown). Since cells expressing recombinant startle disease mutations are not conservative, they may have imposed additional functions on mutated residues GlyRs containing the I244N mutation were characterized by extremely small peak currents (I max , see Table I ), it that were not characteristic of the wild-type GlyR. A more conservative method of assessing the role of each residue would appear that this mutation greatly impaired the efficiency of GlyR expression while leaving the strychnine is to investigate the effect of alanine substitution, since alanine causes minimal disruption to α-helical and β-sheet binding site essentially intact. This interpretation is supported by the observation that when I244 was mutated to structures and is unlikely to introduce additional functions. Accordingly, we analysed consecutive alanine substitution the more conservative alanine, strychnine binding was mutants of all non-alanine residues in the M1-M2 D247A and P250A) and in the M2-M3 loop (S270A, S273A, P275A, V280A and I283A) exhibited phenotypes intracellular loop from W243 to R252 and in the M2-M3 extracellular region from S270 to I283. Each mutant GlyR that were indistinguishable from wild-type GlyRs in both their electrophysiological properties and their ligand bindwas investigated using similar electrophysiological and radioligand binding procedures as previously described.
ing affinities (Tables I and II) . We conclude that such mutated residues do not form part of the agonist transducThe averaged results of all electrophysiological measurements are summarized in Table I and averaged results tion pathway. However, four other mutations in the M2-M3 loop (R271A, K276A, V277A and Y279A) essentially from all radioligand binding studies are summarized in Table II . With the exception of R252A, all mutations abolished the agonist efficacies of β-alanine and taurine (Table I) . For the V277A mutant GlyR, examples of resulted in expressed GlyRs which displayed glycine-gated currents and [ 3 H]strychnine binding. Cells transfected with currents activated by 100 mM concentrations of glycine, β-alanine and taurine are shown in Figure 2A . In this cDNA encoding the R252A mutant GlyR displayed no glycine-gated currents (n ϭ 25 cells) and no significant mutant GlyR, taurine and β-alanine were converted into full antagonists (Table I) . Examples of taurine inhibition [ 3 H]strychnine binding (n ϭ 3), suggesting that the R252A mutation precluded expression of functional GlyRs. This of currents activated by a half-saturating (2 mM) concentration of glycine in this mutant GlyR are shown in Figure  is consistent with the previous observation that other mutations of this residue (R252Q and R252E) prevented 2C. Other characteristics of the V277A mutant GlyR include a large (107-fold) increase in the glycine EC 50 GlyR protein from being inserted into the cell membrane (Langosch et al., 1993) . As discussed above, the I244N, with respect to the wild-type value (Table I and Figure  2D and E), an 8-fold increase in the glycine K i and smaller I244A and W243A mutant GlyRs were also characterized by reduced B max values, suggesting that these residues are (2-fold) increases in the K i values for β-alanine and taurine (Table II) . Very similar electrophysiological and also important for receptor expression.
Several GlyRs mutated in the M1-M2 loop (N245A, pharmacological properties were shared by the R271A, K276A and Y279A mutant GlyRs (Tables I and II) . Table I ). The binding affinities for glycine, β-alanine and taurine in these mutant GlyRs were intermediate between As these mutant GlyRs clearly exhibit the 'complete' disruption phenotype, we conclude that V277 in addition those of wild-type GlyRs and mutant GlyRs displaying the complete disruption phenotype (Table II) . The L274A, to R271, K276 and Y279 comprise crucial elements of the allosteric transduction mechanism.
S278A and K281A mutant GlyRs may therefore be classified as having a 'partial' disruption phenotype. Three additional mutations within the M2-M3 loop resulted in the conversion of β-alanine and taurine from Three mutations in the M1-M2 loop (W243A, I244A and M246A) also reduced the agonist efficacies of full agonists into partial agonists. The mutations which conferred this characteristic were L274A, S278A and β-alanine and taurine. Sample recordings from cells expressing GlyRs mutated in the M1-M2 loop are dis-K281A (Table I ). An example of the reduced agonist efficacy of taurine and β-alanine in the L274A mutant played in Figure 3 . Figure 3A shows examples of saturating agonist responses for the I244A and D247A mutant GlyRs. GlyR is shown in Figure 2A . As expected for competitive partial agonists, taurine and β-alanine also displayed
The latter mutant exhibited a wild-type phenotype (Table  I) and is included for comparison. An example of partial properties of partial antagonists (Table I ). An example of partial inhibition by taurine of glycine-activated currents antagonism by taurine of glycine-gated currents in the I244A mutant GlyR is shown in Figure 3B . The same in the L274A mutant GlyR is displayed in Figure 2B . The L274A, S278A and K281A mutant GlyRs were also mutation also resulted in a dramatically reduced sensitivity (40-fold) to activation by glycine ( Figure 3D and E). characterized by less pronounced (2-and 47-fold) increases in their respective glycine EC 50 values relative to the Averaged dose-response curves for all M1-M2 loop mutations which resulted in conversion of taurine and wild-type value (see Table I and Figure 2D and E). Taurine and β-alanine EC 50 values were also dramatically increased β-alanine into partial agonists are shown in Figure 2E . In terms of their electrophysiological properties, the W243A, over their respective wild-type values ( Figure 2E and I244A and M246A mutant GlyRs exhibit the 'partial' disruption phenotype and therefore also form crucial elements of the allosteric signal transduction mechanism. However, apart from their reduced B max values, the radioligand binding properties of these intracellular mutant GlyRs are indistinguishable from the wild-type GlyR in their K d values for strychnine or in their K i values for glycine, β-alanine and taurine (Table II) .
Increased desensitization rate in W243A and I244A mutant GlyRs An unexpected finding was that the W243A and I244A mutations also conferred a dramatically increased desensitization rate. Following a 2 s application of a saturating concentration (1 mM) of glycine, wild-type GlyR currents declined to an average of 89 Ϯ 3% (Ϯ SEM, n ϭ 14) of their peak values. In contrast, after a 2 s application of 100 mM glycine, currents in W243A and I244A mutant GlyRs had decreased to 11 Ϯ 5% and 10 Ϯ 2% (n ϭ 11 for both) respectively of their peak values. This difference is highly significant (P Ͻ 0.0001, unpaired t-test) for both mutants with respect to the wild-type value. The I244N mutant GlyR also displayed a significantly more rapid rate of desensitization than the wild-type GlyR (mean 77 Ϯ 3%, n ϭ 10, P Ͻ 0.025), but the desensitization rates of all other mutant GlyRs were not significantly different to the wild-type GlyR desensitization rate. Examples of strongly desensitizing responses for the I244A mutant GlyR can be seen in Figure 3 . As displayed in Figure 3C , recovery from desensitization was also rapid, with a half-recovery time of~2 s (n ϭ 2) for the I244A mutant GlyR. group on a single residue may result in a continuum of phenotypes from partial to complete disruption, we examined a series of mutations to R271. This residue was same residue can result in a continuum of phenotypes from partially disrupted to completely disrupted. Although investigated as it has already been characterized via three mutations to differing side chain groups (R271L, R271Q
we were unable to distinguish an obvious correlation between the structural and chemical properties of the and R271A). In an attempt to characterize the side chain characteristics required for minimal disruption to the side chain and the resulting phenotype, these results demonstrate that residues identified by partial disruption transduction process, we constructed and examined the following mutations: R271K, R271H and R271N. The phenotypes contribute to the transduction process. conservative R271K substitution retains the positive charge and large side chain. The R271H substitution conserves Discussion the positive charge but not the large side chain. On the other hand, the R271N substitution is uncharged and polar
The M1-M2 and M2-M3 loops form allosteric signal transduction domains and, like the structurally similar R271Q substitution, may be expected to result in a complete disruption phenotype.
Alanine substitution mutations to a total of four out of 11 possible residues in the M2-M3 loop resulted in the Averaged dose-response curves for glycine, β-alanine and taurine are shown for all R271 mutant GlyRs in Figure 4 . complete disruption phenotype. This phenotype is characterized by a complete loss of agonist efficacy for Surprisingly, these experiments revealed that the R271K, R271H and R271N mutant GlyRs each exhibited the β-alanine and taurine, dramatic increases (Ͼ55-fold) in the glycine EC 50 , the conversion of β-alanine and taurine partial disruption phenotype, in contrast to those of the R271L, R271Q and R271A mutant GlyRs, which each into complete antagonists of glycine-gated currents and large increases in the K i values for glycine relative to exhibited the complete disruption phenotype. As expected for mutant GlyRs with the partial disruption phenotype, those for β-alanine and taurine. In addition, mutations to a further six out of a possible 14 residues throughout the the radioligand binding properties of the R271K, R271H and R271N mutant GlyRs were also intermediate between M1-M2 and M2-M3 loops resulted in a partial disruption phenotype. This phenotype is characterized by the converthose of the wild-type GlyR and the R271L, R271Q and R271A mutant GlyRs (Table II) . Hence, mutations to the sion of taurine and β-alanine from full agonists into partial Residues attached by stems represent the startle disease mutations examined in this study. Lightly shaded residues indicate those startle disease mutations or alanine substitution mutations which resulted in β-alanine and taurine being converted into partial agonists. Darkly shaded residues indicate those mutations which resulted in a complete loss of efficacy for these ligands. Thus, the lightly and darkly shaded residues represent 'partial' disruption and 'complete' disruption phenotypes respectively. Residues outlined in bold indicate those where mutations induced dramatically increased rates of desensitization. (B) Alignment of the M2-M3 signal transduction domains from various members of the ligand-gated ion channel superfamily. Circles indicate residues that convert agonists into antagonists, squares indicate residues that redistribute single channel conductances and diamonds indicate residues that alter allosteric enhancement or Hill coefficients. See text for details.
agonists with partial antagonist efficacy, less dramatic competitive agonist site and an antagonist site. However, as the antagonist subsite model (Laube et al., 1995; increases (2-to 47-fold) in the glycine EC 50 and relatively smaller increases in the K i values for glycine. Figure 5A Schmieden and Betz, 1995) would require a highly specific lesion to disrupt the agonist recognition site selectively in illustrates the locations of the mutations which cause both the complete disruption phenotype (darkly shaded a common ligand binding pocket, it is clearly incompatible with the involvement of numerous intracellular and extraresidues) and the partial disruption phenotype (lightly shaded residues). In addition, mutated residues which cellular residues, as observed in the present study ( Figure  5A ). Hence, our results strongly support the idea that cause an increased desensitization rate are outlined in bold.
Since glycine, β-alanine and taurine share overlapping mutations which convert taurine and β-alanine from agonists into antagonists do indeed act by disrupting the binding sites (Schmieden et al., 1992 (Schmieden et al., , 1993 , any mutation which converts β-alanine and taurine from agonists into allosteric transduction mechanism. This interpretation is also supported by a theoretical analysis using an allosteric antagonists without changing their binding affinities may act by simply disconnecting their binding sites from the receptor model with multiple discrete conformational states (Galzi et al., 1996) . Since numerous residues in both channel activation gate . An alternative proposal is that the R271L and R271Q loops are capable of disrupting the allosteric transduction process, we propose that the M1-M2 and M2-M3 loops mutations selectively disrupt a common agonist recognition subsite and thereby unmask antagonist subsites for act in parallel to transduce the ligand binding signal into channel activation in GlyR. Furthermore, since all β-alanine and taurine (Laube et al., 1995; Schmieden and Betz, 1995) . It is difficult to differentiate between these members of the ligand-gated ion channel superfamily share considerable sequence and structural homology models by analysing mutations of a single residue, as there is no functional difference between an uncoupled (Devillers-Thiery et al., 1993; Karlin and Akabas, 1995) , this model is likely to apply to all members of this reciprocity between transduction and binding processes, binding experiments alone cannot unequivocally define superfamily.
A variety of experimental evidence from various memwhether a residue comprises a binding site or a transduction site (Colquhoun and Farrant, 1993) . We have demonstrated bers of the ligand-gated ion channel superfamily supports the involvement of residues in the M2-M3 loop in that the M1-M2 loop mutations which result in partial disruption phenotypes have K i values for glycine, β-alanine mediating allosteric transformations. In the GlyR α1 subunit, we have demonstrated that the R271L and R271Q
and taurine which are not significantly different to wildtype values (Table II) . However, M2-M3 loop mutations mutations convert the competitive antagonist picrotoxin into an allosterically acting potentiator, suggesting a conwith similar partial disruption phenotypes generally have dramatically increased glycine K i values (Table II) , sugvergence of allosteric pathways (Lynch et al., 1995) . Furthermore, in R271L and R271Q mutant GlyRs, single gesting that the M2-M3 loop interacts more directly with the glycine binding site. Furthermore, the relatively larger channel conductance states are redistributed towards lower unitary levels (Langosch et al., 1994; increases in glycine K i values, compared with those for taurine and β-alanine, imply that the glycine binding site 1995a) without radically changing the anion-cation selectivity ratio or the current-voltage relationship (Rajendra is more directly linked to the M2-M3 loop than are the binding sites for taurine and β-alanine. In this respect, we et al., 1994) . These mutations may therefore prevent allosteric transitions to one or more conducting conformpropose that R271 forms the point of closest functional contact between the M2-M3 loop and the glycine binding ations. A similar interpretation may also apply to the E297S mutation in the GlyR β subunit (Bormann et al., site, as mutations to this residue are characterized by much larger increases in glycine K i values than are 1993) and to the K→M substitution at position ϩ21 of the Xenopus nicotinic acetylcholine receptor (nAChR) γ observed at any other residue (Table II) . subunit (Murray et al., 1995) , which are both homologous to A273 of the GlyR α1 subunit and both also result in Desensitization Mutations to two residues (W243A and I244A) in the significant changes to unitary channel conductances. In both the α7 and β4 nAChRs, the aspartic acid residues at intracellular M1-M2 loop not only partially disrupt the transduction process but also result in a greatly increased the positions corresponding to Y279 and V280 respectively in the GlyR α1 subunit were recently shown to disrupt the rate of desensitization onset and recovery (Figure 3 ). If such a property is conferred by a simple side chain coupling between agonist binding and channel activation (Campos-Caro et al., 1996) . In the GABA A receptor substitution, then a similar property could also be imposed by allosteric interactions converging on this residue. A (GABA A R) ρ1 subunit, the R316A mutation (homologous to position K276 in the GlyR α1 subunit) increased major determinant of desensitization in the related nAChRs and GABA A Rs is the phosphorylation state (Raymond the Hill coefficient for GABA activation, suggesting a modification to the allosteric coupling mechanism (Kusana et al., 1993; Levitan, 1994) . Like these receptors, the GlyR α1 subunit contains functional phosphorylation sites et al., 1994) . Collectively, these results, which are summarized in Figure 5B , support the notion of a common signal in the intracellular M3-M4 loop (Vaello et al., 1994) , but it is as yet unclear as to whether phosphorylation modulates transduction mechanism applying to all ligand-gated ion channel receptors.
the desensitization rate of this receptor. It is, however, tempting to speculate that phosphorylation sites, or other Based on comparison of electron diffraction images of nAChR in the open and closed states, Unwin (1995) intracellular modulatory sites, may control the desensitization rate by interacting with the channel gating mechanism proposed a structural model for the activation of members of this receptor superfamily. The model postulates that in via residues in the M1-M2 loop. the closed state the M2 domains are kinked inwards to constrict the channel pore and upon activation by A common human startle disease phenotype Inherited startle syndromes in humans and a variety of acetylcholine are twisted sideways to create an open passage. This rotation is clearly a crucial step in the animal species are characterized by a reduced glycinergic tone . Molecular analysis transduction process and implies that the intracellular and extracellular loops flanking the M2 domain act as hinges of human startle disease pedigrees has so far identified a total of six mutations, each of which maps to the GlyR to permit this rotation. Consistent with this model, the simplest explanation of our results is that the M1-M2 and α1 subunit (R271L and R271Q, Shiang et al. 1993; I244N, Rees et al., 1994; Y279C, Shiang et al., 1995 ; K276E, the M2-M3 loops act as the hinges and that mutations that disrupt transduction act by preventing this rotation Elmslie et al., 1996; Q266H, Milani et al., 1996) . The disease phenotype conferred by the R271L and R271Q from taking place. However, since other structural rearrangements are also associated with channel activation mutations was characterized by both a reduced glycine efficacy and a reduced single channel conductance (Karlin and Akabas, 1995; Unwin, 1995) , further signal transduction domains may also exist. (Langosch et al., 1994; Rajendra et al., 1994 Rajendra et al., , 1995a . In the present study, we investigated the I244N, Y279C and K276E startle mutations and found in each case that the The M2-M3 loop may interact with the glycine binding site glycine sensitivity was profoundly decreased (Table I ). In addition, the K276E and Y279C mutations resulted in Mutant GlyRs expressing the complete disruption phenotype are also characterized by dramatic increases in the dramatically diminished I max values (11 and 2% respectively of the wild-type value) without corresponding decreglycine K i values (Table II ). An increase in K i is frequently taken as evidence that the mutated residue forms part of ments in the [ 3 H]strychnine B max values (Table II) , strongly suggesting that these mutations also lowered either the a binding domain. However, due to the principle of glucose, pH 7.4 with NaOH. Patch pipettes had tip resistances of 1-4 MΩ single channel conductance or the channel open probwhen filled with the standard intracellular solution containing 145 mM ability, or both. However, in the I244N mutant GlyR, the CsCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 10 mM EGTA, sharp reduction in I max was accompanied by a complete loss pH 7.4 with CsOH. The empirical Hill equation, fitted by a non-linear of [ 3 H]strychnine binding. Since strychnine-inhibitable least squares algorithm, was used to calculate the apparent 50% effective concentrations for activation (EC 50 ) and for inhibition (IC 50 ) under glycine-gated currents were readily observed in these conditions as described in Results. Hill coefficients were also calculated mutant GlyRs, the most likely explanation for the lack of but were excluded from Tables I and II for determined whether reduced GlyR expression also occurs in vivo. The major finding of this study is that numerous residues Software, San Diego, CA).
in both the M1-M2 and M2-M3 loops are involved in the transduction process between ligand binding and channel activation. This conclusion is supported by a
